Clinical trial / 2019
Menaquinone-7 supplementation for 6 months did not significantly decrease vascular calcification in patients with type 2 diabetes and CVD.
In a randomized, double-blind trial, patients with type 2 diabetes and CVD received 360 µg/day menaquinone-7 (MK-7, n=35) or placebo (n=33) for 6 months. Target-to-background ratio (TBR) on 18F-NaF PET scans tended to increase in the MK-7 group compared to placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), but the change was not significant. Log-transformed CT calcification mass did not significantly differ between groups (0.50; 95% CI: -0.23, 1.36; P = 0.18). MK-7 supplementation significantly decreased dp-ucMGP compared with placebo (-205.6 pmol/L; 95% CI: -255.8, -155.3 pmol/L), and no adverse events occurred.
- Study type
- Randomized double-blind placebo-controlled trial
- Who was studied
- 68 men and women with type 2 diabetes and known cardiovascular disease
- What was measured
- Femoral arterial calcification by 18F-NaF PET scans and CT scan, dp-ucMGP levels
THE PAPER
The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial.
Zwakenberg SR, de Jong PA, Bartstra JW, van Asperen R, Westerink J, de Valk H, Slart RHJA, Luurtsema G, Wolterink JM, de Borst GJ, van Herwaarden JA, van de Ree MA, Schurgers LJ, van der Schouw YT, Beulens JWJ. Am J Clin Nutr, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.